Treatment of gastrointestinal stromal tumors
AssigneesNovartis AG, Dana-Farber Cancer Institute, Inc., Oregon Health & Science University
InventorsElisabeth Buchdunger, Renaud Capdeville, George Daniel Demetri, Sasa Dimitrijevic, Brian Jay Druker, Jonathan A. Fletcher, Michael C. Heinrich, Heikki Joensuu, Sandra Leta Silberman, David Tuveson
Life of this patent
Estimating the term…
Abstract
4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
Claims6
A method of treating gastrointestinal stromal tumours which comprises administering to a human in need of such treatment a dose, effective against gastrointestinal stromal tumours, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I
- or a pharmaceutically acceptable salt thereof.
A method for administering to a human subject having gastrointestinal stromal tumours 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyrimidin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I
- or a pharmaceutically acceptable salt thereof, which comprises administering a pharmaceutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof to the human subject once daily for a period exceeding 3 months.
Dependencies are inferred from the claim text.